Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Resmed Inc (NYSE: RMD) closed at $285.17 in the last session, down -0.22% from day before closing price of $285.8. In other words, the price has decreased by -$0.22 from its previous closing price. On the day, 0.85 million shares were traded. RMD stock price reached its highest trading level at $286.91 during the session, while it also had its lowest trading level at $284.21.
Ratios:
We take a closer look at RMD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 34.15 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.13. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 3.44. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.14.
On March 19, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $280.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Hernandez John sold 2,575 shares for $287.10 per share. The transaction valued at 739,289 led to the insider holds 4,045 shares of the business.
Hernandez John bought 2,575 shares of RMD for $739,289 on Aug 18 ’25. On Aug 07 ’25, another insider, Farrell Michael J., who serves as the Chief Executive Officer of the company, sold 8,009 shares for $279.48 each. As a result, the insider received 2,238,379 and left with 455,503 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RMD now has a Market Capitalization of 41753169920 and an Enterprise Value of 41487724544. As of this moment, Resmed’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.99, and their Forward P/E ratio for the next fiscal year is 23.64. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.68. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.11 while its Price-to-Book (P/B) ratio in mrq is 6.99. Its current Enterprise Value per Revenue stands at 8.062 whereas that against EBITDA is 22.3.
Stock Price History:
The Beta on a monthly basis for RMD is 0.85, which has changed by 0.1750381 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, RMD has reached a high of $293.81, while it has fallen to a 52-week low of $199.92. The 50-Day Moving Average of the stock is 5.93%, while the 200-Day Moving Average is calculated to be 16.71%.
Shares Statistics:
According to the various share statistics, RMD traded on average about 911.95K shares per day over the past 3-months and 841650 shares per day over the past 10 days. A total of 146.39M shares are outstanding, with a floating share count of 145.50M. Insiders hold about 0.63% of the company’s shares, while institutions hold 65.31% stake in the company. Shares short for RMD as of 1753920000 were 9019375 with a Short Ratio of 9.89, compared to 1751241600 on 10127096. Therefore, it implies a Short% of Shares Outstanding of 9019375 and a Short% of Float of 7.090000000000001.
Dividends & Splits
The forward annual dividend rate for RMD is 2.19, which was 2.12 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.0074177748The stock’s 5-year Average Dividend Yield is 0.83. The current Payout Ratio is 22.30% for RMD, which recently paid a dividend on 2025-08-14 with an ex-dividend date of 2025-08-14. Stock splits for the company last occurred on 2010-08-31 when the company split stock in a 2:1 ratio.
Earnings Estimates
The stock of Resmed Inc (RMD) is currently in the spotlight, with 11.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $2.69, with high estimates of $2.79 and low estimates of $2.6.
Analysts are recommending an EPS of between $12.0 and $10.32 for the fiscal current year, implying an average EPS of $10.87. EPS for the following year is $11.94, with 18.0 analysts recommending between $12.48 and $11.5.
Revenue Estimates
According to 16 analysts, the current quarter’s revenue is expected to be $1.33B. It ranges from a high estimate of $1.36B to a low estimate of $1.31B. As of the current estimate, Resmed Inc’s year-ago sales were $1.22BFor the next quarter, 16 analysts are estimating revenue of $1.4B. There is a high estimate of $1.43B for the next quarter, whereas the lowest estimate is $1.37B.
A total of 26 analysts have provided revenue estimates for RMD’s current fiscal year. The highest revenue estimate was $5.71B, while the lowest revenue estimate was $5.52B, resulting in an average revenue estimate of $5.61B. In the same quarter a year ago, actual revenue was $5.15BBased on 26 analysts’ estimates, the company’s revenue will be $6.03B in the next fiscal year. The high estimate is $6.2B and the low estimate is $5.87B.
